Pattern classification of volitional functional magnetic resonance imaging responses in patients with severe brain injury.

Bardin JC, Schiff ND, Voss HU. Pattern classification of volitional functional magnetic resonance imaging responses in patients with severe brain injury. Archives Neurology. 2012;69(2):176-81. DOI: 10.1001/archneurol.2011.892. PubMed PMID: 22332186.

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Archives Neurology. 2012;69(2):262-4. DOI: 10.1001/archneurol.2011.1057. PubMed PMID: 22332194.

Stiff-man syndrome and variants: clinical course, treatments, and outcomes.

McKeon A, Robinson MT, McEvoy KM, Matsumoto JY, Lennon VA, Ahlskog JE, et al. Stiff-man syndrome and variants: clinical course, treatments, and outcomes. Archives Neurology. 2012;69(2):230-8. DOI: 10.1001/archneurol.2011.991. PubMed PMID: 22332190.

Peripheral nerve toxic effects of nitrofurantoin.

Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC. Peripheral nerve toxic effects of nitrofurantoin. Archives Neurology. 2012;69(2):265-8. DOI: 10.1001/archneurol.2011.1120. PubMed PMID: 22332195.

Identifying subtle cortical gyral abnormalities as a predictor of focal cortical dysplasia and a cure for epilepsy.

Oster JM, Igbokwe E, Cosgrove GR, Cole AJ. Identifying subtle cortical gyral abnormalities as a predictor of focal cortical dysplasia and a cure for epilepsy. Archives Neurology. 2012;69(2):257-61. DOI: 10.1001/archneurol.2011.1002. PubMed PMID: 21987396.

Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurol

Kinkel RP, Dontchev M, Kollman C, Skaramagas TT, O'Connor PW, Simon JH. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurol. Archives Neurology. 2012;69(2):183-90. DOI: 10.1001/archneurol.2011.1426. PubMed PMID: 21987393.

Immunological markers of optimal response to natalizumab in multiple sclerosis.

Villar LM, García-Sánchez MI, Costa-Frossard L, Espiño M, Roldán E, Páramo D, et al.. Immunological markers of optimal response to natalizumab in multiple sclerosis. Archives Neurology. 2012;69(2):191-7. DOI: 10.1001/archneurol.2011.971. PubMed PMID: 22332187.

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Archives Neurology. 2012;69(2):198-207. DOI: 10.1001/archneurol.2011.1538. PubMed PMID: 21987394.

Archetypal and new families with Alexander disease and novel mutations in GFAP.

Messing A, Li R, Naidu S, Taylor JP, Silverman L, Flint D, et al. Archetypal and new families with Alexander disease and novel mutations in GFAP. Archives Neurology. 2012;69(2):208-14. DOI: 10.1001/archneurol.2011.1181. PubMed PMID: 21987397.

Prediction of cognitive decline by positron emission tomography of brain amyloid and tau.

Small GW, Siddarth P, Kepe V, Ercoli LM, Burggren AC, Bookheimer SY, et al. Prediction of cognitive decline by positron emission tomography of brain amyloid and tau. Archives Neurology. 2012;69(2):215-22. DOI: 10.1001/archneurol.2011.559. PubMed PMID: 22332188.